Related Experiment Video
Updated: Aug 5, 2026
07:38
Induction of Nephrotic Syndrome in Mice by Retrobulbar Injection of Doxorubicin and Prevention of Volume Retention by Sustained Release Aprotinin
Published on: May 6, 2018
Obinutuzumab as a Rescue and Maintenance Strategy in Children with Difficult-to-Treat Nephrotic Syndrome After
Haoqiong Sun1, Ling Guo1, Panpan Shao1
1Department of Pediatrics, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, People's Republic of China.
Drug Design, Development and Therapy
|July 28, 2026
Summary
Obinutuzumab shows promise for difficult-to-treat nephrotic syndrome in children, achieving 100% relapse-free survival and B-cell depletion. This anti-CD20 therapy reduced immunosuppression needs with manageable safety in a small cohort.
Area of Science:
- Pediatric Nephrology
- Immunology
- Pharmacology
Background:
- Nephrotic syndrome in children often requires intensive immunosuppression.
- Rituximab failure or intolerance presents a challenge in managing difficult-to-treat cases.
- Novel anti-CD20 therapies are being explored for refractory pediatric nephrotic syndrome.
Purpose of the Study:
- To evaluate obinutuzumab as a rescue and maintenance therapy for pediatric nephrotic syndrome.
- To assess the effectiveness and safety of obinutuzumab after rituximab failure.
- To explore obinutuzumab's impact on relapse rates and immunosuppression needs.
Main Methods:
- Retrospective, single-center study of children treated with obinutuzumab.
- Inclusion criteria: difficult-to-treat nephrotic syndrome, prior rituximab failure/intolerance.
- Outcomes: 12-month relapse-free survival, B-cell depletion, glucocorticoid-free status, safety.
Main Results:
- 100% relapse-free survival observed in the efficacy set (8/8 patients).
- Complete peripheral B-cell depletion achieved and sustained for at least 6 months.
- Seven of eight patients achieved glucocorticoid-free status; background immunosuppression reduced/discontinued.
- One severe anaphylactic shock event; other infections were low-grade.
Conclusions:
- Obinutuzumab demonstrated a favorable relapse profile in this pediatric cohort.
- Sustained B-cell depletion and reduced immunosuppression were observed.
- Larger prospective studies are needed to confirm efficacy and long-term safety.